Artivion (NYSE:AORT) PT Raised to $30.00

Artivion (NYSE:AORT) had its price objective increased by analysts at Lake Street Capital from $28.00 to $30.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s target price suggests a potential upside of 16.05% from the company’s current price.

A number of other equities analysts have also commented on the company. Needham & Company LLC lifted their price objective on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Stifel Nicolaus upped their price target on Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th.

Artivion Stock Up 0.8 %

Artivion stock opened at $25.85 on Tuesday. The company has a current ratio of 6.04, a quick ratio of 4.26 and a debt-to-equity ratio of 1.07. Artivion has a 1-year low of $12.16 and a 1-year high of $26.26. The firm’s fifty day simple moving average is $23.22 and its 200-day simple moving average is $20.49. The company has a market capitalization of $1.08 billion, a P/E ratio of -107.71 and a beta of 1.75.

Artivion (NYSE:AORT) last posted its earnings results on Monday, May 6th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.04. Artivion had a positive return on equity of 3.64% and a negative net margin of 2.61%. The company had revenue of $97.43 million for the quarter, compared to analyst estimates of $92.30 million. Sell-side analysts forecast that Artivion will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AORT. GAMMA Investing LLC raised its holdings in Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after purchasing an additional 505 shares during the last quarter. Register Financial Advisors LLC bought a new stake in shares of Artivion during the first quarter worth approximately $114,000. Allspring Global Investments Holdings LLC lifted its holdings in Artivion by 291.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after buying an additional 4,154 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Artivion by 25.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock valued at $186,000 after acquiring an additional 2,108 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in Artivion by 7.8% during the 4th quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock worth $239,000 after acquiring an additional 968 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.